Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease

scientific article

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.PARKRELDIS.2014.09.033
P932PMC publication ID4306614
P698PubMed publication ID25434972

P50authorAvi Orr-UrtregerQ64761255
Deborah RaymondQ64856479
Lorraine ClarkQ64858601
Karen S. MarderQ67209635
Susan BressmanQ67212570
Roy N AlcalayQ67215512
Helen Mejia-SantanaQ67242979
Laurie OzeliusQ67426010
Christina PalmeseQ114420377
LRRK2 Ashkenazi Jewish ConsortiumQ114420378
Matthew J BarrettQ56487531
Anat MirelmanQ56769483
Nir GiladiQ64761181
Rachel Saunders-PullmanQ64761222
P2093author name stringElise Caccappolo
P2860cites workLRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sampleQ83916757
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 casesQ29614910
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyQ29614953
Neuropathologic substrates of Parkinson disease dementiaQ30527797
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseQ33723751
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysisQ34140991
Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodiesQ34513753
Changes in motor subtype and risk for incident dementia in Parkinson's diseaseQ34517430
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease studyQ35897974
Clinical and pathological characteristics of LRRK2 G2019S patients with PD.Q35911042
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.Q35938554
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD StudyQ36005602
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutationsQ37385032
Cognitive and motor function in long-duration PARKIN-associated Parkinson diseaseQ37625797
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's diseaseQ37679384
The neuropathology of genetic Parkinson's diseaseQ37997386
LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohortQ38900613
Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's diseaseQ38902628
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriersQ39477657
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's diseaseQ42010008
Cognitive decline in Parkinson's disease: a prospective longitudinal studyQ44789584
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study GroupQ44801417
Clinical features of LRRK2-associated Parkinson's disease in central NorwayQ44830290
A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutationsQ46417649
Brain SPECT analysis by 3D-SSP and phenotype of Parkinson's diseaseQ46849539
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonismQ48248911
Frequency of LRRK2 mutations in early- and late-onset Parkinson diseaseQ48392751
Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype.Q51889070
Cognitive profile of patients with newly diagnosed Parkinson disease.Q51987773
Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.Q54403187
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.Q55041570
The Frequency and Associated Risk Factors for Dementia in Patients With Parkinson's DiseaseQ61881956
The effect of age of onset of PD on risk of dementiaQ61932329
P433issue2
P921main subjectneuropsychologyQ3872
Parkinson's diseaseQ11085
P1104number of pages5
P304page(s)106-110
P577publication date2014-11-20
P1433published inParkinsonism and Related DisordersQ15762600
P1476titleNeuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease
P478volume21

Reverse relations

cites work (P2860)
Q36885946A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis
Q35850713Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
Q39206423Clinical Features of LRRK2 Carriers with Parkinson's Disease
Q57072461Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-Analysis
Q89776335Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study
Q37305731Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease
Q39967268Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers
Q92933189LRRK2 in Parkinson disease: challenges of clinical trials
Q38376569Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease
Q39841718Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease
Q35772821Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene
Q90194740Postural Instability in Parkinson's Disease: A Review
Q47198236Progression in the LRRK2-Asssociated Parkinson Disease Population
Q36470291REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers
Q91774191Systematic review of genetic variants associated with cognitive impairment and depressive symptoms in Parkinson's disease
Q40783163The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot

Search more.